Medicare Enrolled
Dr. Ellsworth Grant, M.D
Hematology & Oncology · Los Angeles, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Grant from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Grant?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Grant
Dr. Ellsworth Grant is a hematology & oncology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Grant performed 3,643 Medicare services across 472 unique beneficiaries.
Between the years covered by Open Payments, Dr. Grant received a total of $20,711 from 84 pharmaceutical and/or device companies across 908 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Grant is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 35% volume in CA
$20,711 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,643
Medicare services
Top 35% in CA for hematology & oncology
472
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~192 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 952 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
752 | $0 | $0 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
314 | $1 | $2 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
277 | $12 | $34 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
255 | $96 | $272 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
181 | $1 | $2 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
170 | $12 | $30 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
135 | $8 | $13 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
94 | $67 | $168 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
93 | $53 | $148 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
86 | $120 | $306 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
81 | $7 | $17 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
66 | $26 | $66 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
65 | $25 | $65 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
24 | $17 | $45 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
24 | $140 | $379 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
23 | $21 | $60 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
23 | $52 | $192 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
15 | $108 | $367 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
13 | $66 | $192 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.4% high complexity
74.3% medium
13.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$20,711
Total received (2018-2024)
Avg $2,959/year across 7 years
Top 20% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
84
Companies
908
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,464 (84.3%)
Other
Charitable contributions, space rental, and other categories
$2,241 (10.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$856 (4.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$150 (0.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,703
2023
$3,848
2022
$3,820
2021
$2,752
2020
$1,724
2019
$2,173
2018
$2,692
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,242
PFIZER INC.
$387
E.R. Squibb & Sons, L.L.C.
$289
Incyte Corporation
$209
Daiichi Sankyo Inc.
$152
Merck Sharp & Dohme LLC
$139
Astellas Pharma US Inc
$132
AstraZeneca Pharmaceuticals LP
$120
Exelixis Inc.
$85
Karyopharm Therapeutics Inc.
$79
Celgene Corporation
$73
ABBVIE INC.
$69
Bayer Healthcare Pharmaceuticals Inc.
$59
PROGENICS PHARMACEUTICALS, INC.
$57
PharmaEssentia USA Corporation
$52
Takeda Pharmaceuticals U.S.A., Inc.
$52
Genentech USA, Inc.
$51
Eisai Inc.
$46
Janssen Biotech, Inc.
$45
ARRAY BIOPHARMA INC
$44
Chiesi USA, Inc.
$38
Genmab U.S., Inc.
$32
GlaxoSmithKline, LLC.
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$29
Mirati Therapeutics, Inc.
$28
PUMA BIOTECHNOLOGY, INC.
$27
SUN PHARMACEUTICAL INDUSTRIES INC.
$26
Agios Pharmaceuticals, Inc.
$25
Novocure Inc.
$25
Coherus Biosciences Inc.
$22
Azurity Pharmaceuticals, Inc.
$18
Emmaus Medical, Inc.
$18
Top 3 companies account for 51.8% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$2,975
PFIZER INC.
$1,454
E.R. Squibb & Sons, L.L.C.
$1,421
Janssen Biotech, Inc.
$1,101
Amgen Inc.
$1,098
Genentech USA, Inc.
$928
AstraZeneca Pharmaceuticals LP
$902
Celgene Corporation
$784
Incyte Corporation
$717
Exelixis Inc.
$651
Takeda Pharmaceuticals U.S.A., Inc.
$573
Astellas Pharma US Inc
$561
GENZYME CORPORATION
$447
Pharmacyclics LLC, An AbbVie Company
$433
Merck Sharp & Dohme LLC
$419
Daiichi Sankyo Inc.
$331
NOVARTIS PHARMACEUTICALS CORPORATION
$283
Karyopharm Therapeutics Inc.
$269
Gilead Sciences, Inc.
$259
GlaxoSmithKline, LLC.
$232
EISAI INC.
$206
Seattle Genetics, Inc.
$197
Merck Sharp & Dohme Corporation
$190
Blueprint Medicines Corporation
$183
Alexion Pharmaceuticals, Inc.
$179
Eisai Inc.
$173
Emmaus Medical, Inc.
$172
Bayer HealthCare Pharmaceuticals Inc.
$171
Secura Bio, Inc.
$169
PharmaEssentia USA Corporation
$161
Boehringer Ingelheim Pharmaceuticals, Inc.
$159
COMSORT, Inc
$150
Global Blood Therapeutics, Inc.
$150
EMD Serono, Inc.
$149
Mirati Therapeutics, Inc.
$145
Chiesi USA, Inc.
$128
Teva Pharmaceuticals USA, Inc.
$119
ABBVIE INC.
$115
Seagen Inc.
$115
Bayer Healthcare Pharmaceuticals Inc.
$106
Puma Biotechnology, Inc.
$97
Taiho Oncology, Inc.
$94
SANOFI-AVENTIS U.S. LLC
$87
Alnylam Pharmaceuticals Inc.
$83
ADC Therapeutics America, Inc.
$78
TOLMAR Pharmaceuticals, Inc.
$65
EUSA Pharma (US) LLC
$64
PROGENICS PHARMACEUTICALS, INC.
$57
Foundation Medicine, Inc.
$56
Coherus Biosciences Inc.
$56
Lilly USA, LLC
$55
Organon LLC
$54
PUMA BIOTECHNOLOGY, INC.
$52
MorphoSys, US Inc.
$50
ARRAY BIOPHARMA INC
$44
Agios Pharmaceuticals, Inc.
$43
Pharmacosmos Therapeutics Inc.
$42
Sun Pharmaceutical Industries Inc.
$41
Clovis Oncology, Inc.
$40
BeiGene USA, Inc.
$32
Genmab U.S., Inc.
$32
Adaptive Biotechnologies Corporation
$30
Dendreon Pharmaceuticals LLC
$28
ImmunoGen, Inc.
$28
PORTOLA PHARMACEUTICALS, INC.
$28
Pharmacyclics LLC, an AbbVie Company
$28
Amneal Pharmaceuticals LLC
$28
SUN PHARMACEUTICAL INDUSTRIES INC.
$26
AbbVie Inc.
$25
Verity Pharmaceuticals Inc.
$25
Novocure Inc.
$25
Terumo BCT, Inc.
$24
TAIHO ONCOLOGY, INC.
$24
Regeneron Healthcare Solutions, Inc.
$24
Sumitomo Pharma America, Inc.
$23
Ipsen Biopharmaceuticals, Inc
$22
Progenics Pharmaceuticals, Inc.
$20
MEDIVATION FIELD SOLUTIONS LLC
$19
Azurity Pharmaceuticals, Inc.
$18
Janssen Pharmaceuticals, Inc
$17
Collegium Pharmaceutical, Inc.
$16
Dova Pharmaceuticals
$14
Myriad Genetic Laboratories, Inc.
$12
Advanced Accelerator Applications
$12
Top 3 companies account for 28.2% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AVASTIN · AYVAKIT · Alecensa · Aranesp · Avastin · BAVENCIO · BENDEKA · BESREMI · BEVYXXA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · Cabometyx · DARZALEX · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Elahere · Endari · Enhertu · Epkinly · Erleada · FARYDAK · FERRIPROX · FOUNDATIONONE · Fabhalta · Farydak · GAVRETO · GILOTRIF · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JADENU · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Optune · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · PYLARIFY · PYRUKYND · Pomalyst · Prolia · REBLOZYL · RETACRIT · RYBREVANT · RYDAPT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SUTENT · Spectra Optia Apheresis System · Stivarga · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TIVDAK · TUKYSA · Tecentriq · Trelstar · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VIVIMUSTA · Venclexta · Vyloy · XALKORI · XPOVIO · XTAMPZA · XTANDI · XYNTHA · Xofigo · Xospata · Xtandi · YONSA · ZEJULA · ZYTIGA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (84%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
406
Per 100K population
4.1
County median income
$87,760
Nearest hospital
PIH HEALTH GOOD SAMARITAN HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Grant is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 20% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Grant experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Grant performed 952 anti-nausea injection (ondansetron/zofran) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Grant receive payments from pharmaceutical companies?
Yes. Dr. Grant received a total of $20,711 from 84 companies across 908 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Grant's costs compare to other hematology & oncology specialists in Los Angeles?
Dr. Grant's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Grant) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Los Angeles
Browse hematology & oncology specialists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology